EGFR and neoplasm: Greater infiltration of T-cells in general, as well as CD8+ T-cells and B cells, in the TME upon EGFR inhibition was further observed in immunohistochemistry staining of tumour sections from samples treated with either erlotinib or aPD-1 + erlotinib (Figure S1).